Sensorion (EPA: ALSEN) reported six-month follow-up data from its Audiogene Phase 1/2 trial showing sustained early efficacy signals for SENS-501 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE